Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence

Abstract

The aim of this study was to assess the effectiveness and safety of intracavernous injections of a fourdrug vasoactive mixture in diabetic patients with organic impotence. A group of 60 diabetic patients with either pure neurogenic, pure vasculogenic or mixed neurovasculogenic impotence were treated with intracavernous injections of a combination of 12.1 mg/ml papaverine hydrochloride, 1.01 mg/ml phentolamine mesylate, 10.1 μg/ml prostaglandin E1 and 0.15 mg/ml atropine sulphate (‘full-dose’ mixture). A mixture of the same drugs but at one-third concentrations (‘reduced-dose” mixture) was also used. The mean (±SEM) volumes of the full-dose and reduced-dose mixtures used were 0.21±0.03 ml and 0.31±0.02 ml, respectively. All the patients were able to sustain a rigid erection at the end of the titration phase of the study. At a mean follow-up of 18 months, 48 patients (80%) were successfully using the mixture, 6 patients (10%) were using the mixture at a dose lower than the initial dose and 6 patients (10%) had dropped out from the injection therapy. No major complications were seen. The association of multiple vasoactive drugs which use different mechanisms of action, thus exerting a pharmacological synergism, is an effective and safe procedure in intracavernous pharmacotherapy for diabetic patients with organic impotence.